Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung

被引:31
作者
Escofier, N
Boichot, E
Germain, N
Silva, PMRE
Martins, MA
Lagente, V
机构
[1] Univ Rennes 1, Fac Sci Pharmaceut & Biol, Lab Pharmacodynam & Pharmacol Mol, INSERM,U456, F-35043 Rennes, France
[2] Inst Oswaldo Cruz, FIOCRUZ, Dept Fisiol & Farmacodinam, BR-20001 Rio De Janeiro, Brazil
关键词
cyclic AMP; interleukin-10; phosphodiesterase inhibitors; rats; TNF-alpha;
D O I
10.1111/j.1472-8206.1999.tb00326.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to investigate the effects of IL-10, a cell permeable analogue of cyclic AMP, dibutyryl-cAMP (db-cAMP), modulators of intracellular cyclic AMP such as phosphodiesterase (PDE) inhibitors and a beta(2)-adrenoceptor agonist, salmeterol, on pulmonary inflammation following acute lung injury induced by endotoxin exposure in rats. Pulmonary inflammation was induced in adult Wistar rats by a 60-min exposure to endotoxin (lipopolysaccharide, LPS, 100 mu g/mL). 4 h later bronchoalveolar lavage (BAL) was performed. The PDE inhibitors, rolipram (3 and 5 mg/kg) and theophylline (30 and 100 mg/kg) inhibited neutrophil recruitment, TNF-alpha release and cellular activation in BAL. Salmeterol (0.5 mg/mL) and IL-10 (0.1 mu g) only inhibit TNF-alpha increase in the BAL fluid and db-AMPc (2.5 mu g/rat) was ineffective. The present data show that the selective PDE4 inhibitor, rolipram, and the non-selective PDE inhibitor, theophylline, markedly reduced the pulmonary inflammation associated with acute lung injury in the rat. These effects may be mediated in part by IL-10 rather than by cyclic AMP, as demonstrated by the potent inhibitory activity of exogenous IL-10 on the increase in TNF-alpha release in BAL fluid of rats exposed to LPS. (C) Elsevier, Paris.
引用
收藏
页码:96 / 101
页数:6
相关论文
共 27 条
  • [1] Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro
    Anderson, R
    Feldman, C
    Theron, AJ
    Ramafi, G
    Cole, PJ
    Wilson, R
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (07) : 1387 - 1394
  • [2] BEAVO JA, 1994, MOL PHARMACOL, V46, P399
  • [3] Salmeterol inhibition of mediator release from human lung mast cells by β-adrenoceptor-dependent and independent mechanisms
    Chong, LK
    Cooper, E
    Vardey, CJ
    Peachell, PT
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (05) : 1009 - 1015
  • [4] A MOUSE MODEL OF LUNG INJURY-INDUCED BY MICROBIAL PRODUCTS - IMPLICATION OF TUMOR-NECROSIS-FACTOR
    DENIS, M
    LIU, GJ
    WIDMER, M
    CANTIN, A
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1994, 10 (06) : 658 - 664
  • [5] Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production
    Eigler, A
    Siegmund, B
    Emmerich, U
    Baumann, KH
    Hartmann, G
    Endres, S
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 63 (01) : 101 - 107
  • [6] Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs
    Germain, N
    Bertin, B
    Legendre, A
    Martin, B
    Lagente, V
    Payne, A
    Boichot, E
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1998, 12 (06) : 1334 - 1339
  • [7] HICHAMI A, 1995, EUR J PHARM-MOLEC PH, V291, P91, DOI 10.1016/0014-2999(95)90083-7
  • [8] Phosphodiesterase 4 inhibitors and db-cAMP inhibit TNF-alpha release from human mononuclear cells. Effects of cAMP and cGMP-dependent protein kinase inhibitors
    Hichami, A
    Boichot, E
    Germain, N
    Berdyshev, E
    Coqueret, O
    Lagente, V
    [J]. MEDIATORS OF INFLAMMATION, 1996, 5 (06) : 425 - 428
  • [9] HICHAMI A, 1996, LIFE SCI, V59, P255
  • [10] HOWELL RE, 1995, J PHARMACOL EXP THER, V275, P703